Sandoz/Momenta nab 1st US generic Copaxone; launch unclear
This article was originally published in Scrip
Executive Summary
The FDA on 16 April granted Novartis unit Sandoz and its partner Momenta Pharmaceuticals approval to market the first generic version of Teva's big moneymaker Copaxone (glatiramer acetate injection), which is approved in the US to treat multiple sclerosis.